journal article·2014-10

Sustained delivery of latanoprost by thermosensitive chitosan–gelatin-based hydrogel for controlling ocular hypertension

Yung-Hsin Cheng, Kuo-Hsuan Hung, Tung-Hu Tsai, Chia-Jung Lee, Ruy-Yu Ku, Allen Wen-hsiang Chiu, Shih-Hwa Chiou, Catherine Jui-ling Liu

Acta Biomaterialia· Volume 10· Issue 10
Publisher page

Abstract

Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1min at 37°C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Glaucoma and retinal disorders · Ocular Surface and Contact Lens · Corneal Surgery and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review10.2165/00002512-200522040-00004 ↗
2. Novel drug delivery systems for glaucoma10.1038/eye.2011.82 ↗
3. Pharmacological management of ocular hypertension: current approaches and future prospective10.1016/j.coph.2012.09.012 ↗
4. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
5. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance10.5301/ejo.5000006 ↗
6. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma10.1016/S0002-9394(02)01827-5 ↗
7. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions10.1016/j.otohns.2003.07.005 ↗
8. Preservatives in eyedrops: the good, the bad and the ugly10.1016/j.preteyeres.2010.03.001 ↗
9. Ocular drug delivery: a clue from nanotechnology10.3389/fphar.2012.00188 ↗
10. Nanostructured mucoadhesive microparticles for enhanced preocular retention10.1016/j.actbio.2013.08.026 ↗
11. In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate10.1016/j.actbio.2013.09.024 ↗
12. Optimization of subconjunctival biodegradable microfilms for sustained drug delivery to the anterior segment in a small animal model10.1167/iovs.12-11466 ↗
13. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma10.1097/IJG.0b013e3181c4b0e8 ↗
14. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
15. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye10.1371/journal.pone.0024513 ↗
16. Novel injectable neutral solutions of chitosan form biodegradable gels in situ10.1016/S0142-9612(00)00116-2 ↗
17. The potential of chitosan-based gels containing intervertebral disc cells for nucleus pulposus supplementation10.1016/j.biomaterials.2005.06.037 ↗
18. Pseudo-thermosetting chitosan hydrogels for biomedical application10.1016/j.ijpharm.2004.07.037 ↗
19. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel10.1016/S0939-6411(03)00095-X ↗
20. Thermosensitive chitosan-gelatin-glycerol phosphate hydrogels as a cell carrier for nucleus pulposus regeneration: an in-vitro study10.1089/ten.tea.2009.0229 ↗
21. Thermosensitive chitosan-gelatin-glycerol phosphate hydrogel as a controlled release system of ferulic acid for nucleus pulposus regeneration10.1016/j.biomaterials.2011.03.065 ↗
22. Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits
23. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration10.1089/jop.2011.0215 ↗
24. Corticosteroid-induced glaucoma: a review of the literature10.1038/sj.eye.6701895 ↗
25. Intravitreal triamcinolone acetonide and intraocular pressure10.1016/j.ajo.2004.06.067 ↗
26. Barriers to glaucoma drug delivery10.1097/IJG.0b013e31814b990d ↗
27. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review10.1016/j.carbpol.2012.04.057 ↗
28. Chitins and chitosans for the repair of wounded skin, nerve, cartilage and bone10.1016/j.carbpol.2008.11.002 ↗
29. In vitro characterization of chitosan-gelatin scaffolds for tissue engineering10.1016/j.biomaterials.2005.05.036 ↗
30. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use10.1016/S0939-6411(03)00187-5 ↗
31. Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials10.1016/S0142-9612(02)00004-2 ↗
32. Biocompatibility and characteristics of injectable chitosan-based thermosensitive hydrogel for drug delivery10.1016/j.carbpol.2010.10.022 ↗
33. Primary open-angle glaucoma10.1056/NEJMra0804630 ↗